{"id":"lorcaserin-hcl","safety":{"commonSideEffects":[{"rate":"18","effect":"Headache"},{"rate":"10","effect":"Dizziness"},{"rate":"9","effect":"Nausea"},{"rate":"7","effect":"Fatigue"},{"rate":"6","effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL360328","moleculeType":"Small molecule","molecularWeight":"195.69"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lorcaserin selectively binds to and activates the 5-HT2C receptor in the hypothalamus, a brain region that regulates appetite and energy expenditure. This activation leads to decreased hunger signals and increased feelings of fullness, resulting in reduced caloric intake and weight loss. The selectivity for 5-HT2C over other serotonin receptors (particularly 5-HT2B) was designed to minimize cardiac valvulopathy risk associated with non-selective serotonergic agents.","oneSentence":"Lorcaserin is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:08.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in obese or overweight adults with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT06090461","phase":"","title":"Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2014-09","conditions":"Obesity","enrollment":31889},{"nctId":"NCT02400359","phase":"PHASE4","title":"Lorcaserin in Obesity: Identification of CNS Targets Using FMRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-10","conditions":"Obesity, Weight Loss","enrollment":40},{"nctId":"NCT03338296","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2017-09-28","conditions":"Obesity","enrollment":278},{"nctId":"NCT04205071","phase":"PHASE1","title":"Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2020-11-01","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT03007394","phase":"PHASE2","title":"Lorcaserin in the Treatment of Cocaine Use Disorder","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-12-19","conditions":"Cocaine-Related Disorders","enrollment":272},{"nctId":"NCT02537873","phase":"PHASE1","title":"Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-07","conditions":"Cocaine Use Disorder","enrollment":29},{"nctId":"NCT00603902","phase":"PHASE3","title":"BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":"Obesity","enrollment":4008},{"nctId":"NCT00395135","phase":"PHASE3","title":"BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-11","conditions":"Obesity","enrollment":3182},{"nctId":"NCT00603291","phase":"PHASE3","title":"BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12","conditions":"Obesity","enrollment":604},{"nctId":"NCT01987427","phase":"PHASE4","title":"A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-10-30","conditions":"Chronic Weight Management","enrollment":344},{"nctId":"NCT02022956","phase":"PHASE1","title":"Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-12","conditions":"Pharmacokinetics in Obese Adolescents","enrollment":8},{"nctId":"NCT00829140","phase":"PHASE1","title":"To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-11","conditions":"Obesity","enrollment":56},{"nctId":"NCT02019264","phase":"PHASE4","title":"A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-01-24","conditions":"Cardiovascular Disease, High Cardiovascular Risk, Obesity","enrollment":14673},{"nctId":"NCT02044874","phase":"PHASE2","title":"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation","status":"COMPLETED","sponsor":"Arena Pharmaceuticals","startDate":"2014-03","conditions":"Smoking Cessation","enrollment":603},{"nctId":"NCT03812523","phase":"PHASE2","title":"Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Southeastern Regional Medical Center","startDate":"2019-06","conditions":"Chemotherapy-Induced Peripheral Neuropathy","enrollment":50},{"nctId":"NCT02398669","phase":"PHASE1","title":"A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2015-03","conditions":"Obesity","enrollment":10}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"FEELING COLD"},{"count":1,"reaction":"FEELING HOT"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"POLLAKIURIA"},{"count":1,"reaction":"SOMNOLENCE"},{"count":1,"reaction":"THIRST"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Belviq","placebo Belviq","Belviq XR®"],"phase":"marketed","status":"active","brandName":"Lorcaserin HCl","genericName":"Lorcaserin HCl","companyName":"Beth Israel Deaconess Medical Center","companyId":"beth-israel-deaconess-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lorcaserin is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite. Used for Chronic weight management in obese or overweight adults with weight-related comorbidities.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}